(Q39573613)

13 September 2017

title

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

Kinzie JL

1

1 reference

13 September 2017

Naylor PH

2

1 reference

13 September 2017

Nathani MG

3

1 reference

13 September 2017

Peleman RR

4

1 reference

13 September 2017

Ehrinpreis MN

5

1 reference

13 September 2017

Lybik M

6

1 reference

13 September 2017

Turner JR

7

1 reference

13 September 2017

Janisse JJ

8

1 reference

13 September 2017

Massanari M

9

1 reference

13 September 2017

Mutchnick MG

10

1 reference

13 September 2017

publication date

1 July 2001

1 reference

Journal of Viral Hepatitis

13 September 2017

published in

1 reference

13 September 2017

volume

8

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

264-269

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Consensus interferon: a novel interferon for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Predictors of response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00292.X

10.1046/J.1365-2893.2001.00292.X

21 January 2018

Identifiers

DOI

1 reference

release_favcz22b3ff5jm6vgcub5bunhy

13 September 2017

Fatcat ID

0 references

1 reference